Lancet oncol: Prognosis for radiation therapy in patients with oligocranscater metastasis solid tumors using stereotactic ablation

Stereotactic ablation radiation therapy (SABR) is increasingly being used to treat oligarchic cancer, but there is no high level of evidence for policy development.
this paper reports the results of a national study of patients with extracranial oligopolytic tumors treated with SABR, the largest data set ever learned.
the trial was a forward-looking, one-arm study of patients with neurotic metastasis in patients treated with SABR.
radiotherapy dose is 24-60 Gy, 3-8 times.
The subjects were patients with primary cancer (excluding blood malignancies) with 1-3 intracranial metastatic lesions over the age of 18, and required a disease-free interval of more than 6 months from primary tumor to metastasis, with a life expectancy of at least 6 months.
main prognosmation is the overall survival rate of 1 and 2 years after starting SABR treatment.
June 15, 2015 - January 30, 2019, 1,422 patients were recruited.
69 years of age, the most common primary tumor was prostate cancer (406 cases .28.6 per cent).
follow-up for 13 months (IQR 6-23).
survival rates were 92.3 per cent and 79.2 per cent, respectively, over the past 1 and 2 years.
level 3 adverse reactions were fatigue (2.0%) and the most common severe adverse reactions (4 levels) were elevated liver enzymes (0.6%).
no treatment-related deaths were reported.
the study, the use of SABR in patients with oligocranspheric metastatic cancer was associated with high total survival and low toxicity, complementing the available evidence.
based on the screening criteria for this study, the NHS in England commissioned SABR as a treatment option for patients with oligopolytic diseases in March 2020.
。